Does the media refer more to BIIB or PTGX?

In the previous week, Biogen had 6 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 8 mentions for Biogen and 2 mentions for Protagonist Therapeutics. Biogen's average media sentiment score of 1.02 beat Protagonist Therapeutics' score of 0.83 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PTGX or INSM?

In the previous week, Insmed had 3 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 5 mentions for Insmed and 2 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.83 beat Insmed's score of 0.59 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PTGX or ROIV?

In the previous week, Roivant Sciences had 1 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 3 mentions for Roivant Sciences and 2 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.83 beat Roivant Sciences' score of -0.54 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative

Does the media refer more to PTGX or INCY?

In the previous week, Incyte had 21 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 23 mentions for Incyte and 2 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.83 beat Incyte's score of 0.62 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 7 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Protagonist Therapeutics (PTGX) Competitors

$140.29 +1.10 (+0.79%)

As of 12:24 PM Eastern

Compare

PTGX vs. BIIB, ALNY, INSM, ROIV, and INCY

Should you buy Protagonist Therapeutics stock or one of its competitors? Protagonist Therapeutics's main competitors and comparable companies include Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Insmed (INSM), Roivant Sciences (ROIV), and Incyte (INCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Protagonist Therapeutics compare to Biogen?

Biogen (NASDAQ:BIIB) and Protagonist Therapeutics (NASDAQ:PTGX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

87.9% of Biogen shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Biogen had 6 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 8 mentions for Biogen and 2 mentions for Protagonist Therapeutics. Biogen's average media sentiment score of 1.02 beat Protagonist Therapeutics' score of 0.83 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biogen has higher revenue and earnings than Protagonist Therapeutics. Biogen is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.30	$1.29B	$5.65	39.15
Protagonist Therapeutics	$46.02M	196.84	-$130.15M	$1.03	135.91

Protagonist Therapeutics has a net margin of 29.40% compared to Biogen's net margin of 8.32%. Protagonist Therapeutics' return on equity of 12.03% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Protagonist Therapeutics	29.40%	12.03%	11.23%

Biogen presently has a consensus target price of $230.14, suggesting a potential upside of 4.03%. Protagonist Therapeutics has a consensus target price of $147.13, suggesting a potential upside of 5.10%. Given Protagonist Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protagonist Therapeutics is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.89

Biogen has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market.

Summary

Protagonist Therapeutics beats Biogen on 10 of the 17 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Protagonist Therapeutics (NASDAQ:PTGX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

In the previous week, Alnylam Pharmaceuticals had 5 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 7 mentions for Alnylam Pharmaceuticals and 2 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.83 beat Alnylam Pharmaceuticals' score of 0.19 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protagonist Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alnylam Pharmaceuticals has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market.

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Alnylam Pharmaceuticals currently has a consensus price target of $366.90, indicating a potential upside of 64.48%. Protagonist Therapeutics has a consensus price target of $147.13, indicating a potential upside of 5.10%. Given Alnylam Pharmaceuticals' higher possible upside, research analysts clearly believe Alnylam Pharmaceuticals is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.89

Alnylam Pharmaceuticals has higher revenue and earnings than Protagonist Therapeutics. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	8.04	$313.75M	$5.38	41.46
Protagonist Therapeutics	$46.02M	196.84	-$130.15M	$1.03	135.91

Protagonist Therapeutics has a net margin of 29.40% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Protagonist Therapeutics	29.40%	12.03%	11.23%

Summary

Alnylam Pharmaceuticals and Protagonist Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Insmed?

Protagonist Therapeutics (NASDAQ:PTGX) and Insmed (NASDAQ:INSM) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

In the previous week, Insmed had 3 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 5 mentions for Insmed and 2 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.83 beat Insmed's score of 0.59 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protagonist Therapeutics has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market. Comparatively, Insmed has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

Protagonist Therapeutics has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	196.84	-$130.15M	$1.03	135.91
Insmed	$606.42M	39.26	-$1.28B	-$4.11	N/A

98.6% of Protagonist Therapeutics shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by insiders. Comparatively, 2.1% of Insmed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Protagonist Therapeutics has a net margin of 29.40% compared to Insmed's net margin of -76.94%. Protagonist Therapeutics' return on equity of 12.03% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	29.40%	12.03%	11.23%
Insmed	-76.94%	-123.94%	-44.30%

Protagonist Therapeutics presently has a consensus price target of $147.13, suggesting a potential upside of 5.10%. Insmed has a consensus price target of $200.57, suggesting a potential upside of 83.97%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.89
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Protagonist Therapeutics beats Insmed on 11 of the 17 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Roivant Sciences?

Protagonist Therapeutics (NASDAQ:PTGX) and Roivant Sciences (NASDAQ:ROIV) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

In the previous week, Roivant Sciences had 1 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 3 mentions for Roivant Sciences and 2 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.83 beat Roivant Sciences' score of -0.54 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Negative

98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 8.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Protagonist Therapeutics has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

Protagonist Therapeutics presently has a consensus price target of $147.13, indicating a potential upside of 5.10%. Roivant Sciences has a consensus price target of $45.64, indicating a potential upside of 27.83%. Given Roivant Sciences' higher probable upside, analysts clearly believe Roivant Sciences is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.89
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Protagonist Therapeutics has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	196.84	-$130.15M	$1.03	135.91
Roivant Sciences	$8.26M	3,121.89	-$299.77M	-$0.53	N/A

Protagonist Therapeutics has a net margin of 29.40% compared to Roivant Sciences' net margin of -3,534.96%. Protagonist Therapeutics' return on equity of 12.03% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	29.40%	12.03%	11.23%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

Summary

Protagonist Therapeutics beats Roivant Sciences on 12 of the 17 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Incyte?

Protagonist Therapeutics (NASDAQ:PTGX) and Incyte (NASDAQ:INCY) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 16.2% of Incyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Incyte had 21 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 23 mentions for Incyte and 2 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.83 beat Incyte's score of 0.62 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	7 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protagonist Therapeutics has a net margin of 29.40% compared to Incyte's net margin of 27.71%. Incyte's return on equity of 29.93% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	29.40%	12.03%	11.23%
Incyte	27.71%	29.93%	22.88%

Incyte has higher revenue and earnings than Protagonist Therapeutics. Incyte is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	196.84	-$130.15M	$1.03	135.91
Incyte	$5.14B	4.59	$1.29B	$7.85	14.81

Protagonist Therapeutics has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market. Comparatively, Incyte has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

Protagonist Therapeutics currently has a consensus price target of $147.13, suggesting a potential upside of 5.10%. Incyte has a consensus price target of $126.15, suggesting a potential upside of 8.48%. Given Incyte's higher possible upside, analysts plainly believe Incyte is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.89
Incyte	0 Sell rating(s)	12 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.56

Summary

Incyte beats Protagonist Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Protagonist Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTGX vs. The Competition

Export

Metric	Protagonist Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.04B	$3.84B	$7.13B	$13.27B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	135.59	13.60	273.99	26.15
Price / Sales	196.84	1,296.00	608.65	93.06
Price / Cash	N/A	121.76	77.38	51.25
Price / Book	14.24	16.57	10.88	6.34
Net Income	-$130.15M	-$22.67M	$3.50B	$361.18M
7 Day Performance	-1.31%	-2.20%	-1.62%	-1.17%
1 Month Performance	-4.16%	-10.00%	-5.90%	-3.40%
1 Year Performance	115.45%	22.34%	9.47%	3.28%

Protagonist Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTGX Protagonist Therapeutics	1.675 of 5 stars	$140.29 +0.8%	$147.13 +4.9%	+117.5%	$9.07B	$46.02M	136.05	141
BIIB Biogen	2.8098 of 5 stars	$227.60 +0.5%	$230.14 +1.1%	+44.5%	$33.45B	$9.89B	40.28	7,500	Positive News
ALNY Alnylam Pharmaceuticals	3.9168 of 5 stars	$255.96 +2.6%	$367.20 +43.5%	-49.8%	$33.40B	$3.71B	47.58	2,770	Analyst Forecast
INSM Insmed	3.6153 of 5 stars	$117.83 -3.1%	$201.87 +71.3%	-26.3%	$26.54B	$606.42M	N/A	1,664	Analyst Forecast
ROIV Roivant Sciences	2.6368 of 5 stars	$35.80 -0.9%	$45.64 +27.5%	+125.4%	$26.10B	$8.26M	N/A	721

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTGX) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Protagonist Therapeutics (PTGX) Competitors

PTGX vs. BIIB, ALNY, INSM, ROIV, and INCY

How does Protagonist Therapeutics compare to Biogen?

Summary

How does Protagonist Therapeutics compare to Alnylam Pharmaceuticals?

Summary

How does Protagonist Therapeutics compare to Insmed?

Summary

How does Protagonist Therapeutics compare to Roivant Sciences?

Summary

How does Protagonist Therapeutics compare to Incyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTGX vs. The Competition

Protagonist Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Protagonist Therapeutics (PTGX) Competitors

PTGX vs. BIIB, ALNY, INSM, ROIV, and INCY

How does Protagonist Therapeutics compare to Biogen?

Do institutionals and insiders have more ownership in BIIB or PTGX?

Does the media refer more to BIIB or PTGX?

Which has better valuation and earnings, BIIB or PTGX?

Is BIIB or PTGX more profitable?

Do analysts rate BIIB or PTGX?

Which has more risk and volatility, BIIB or PTGX?

Summary

How does Protagonist Therapeutics compare to Alnylam Pharmaceuticals?

Does the media favor ALNY or PTGX?

Which has more volatility & risk, ALNY or PTGX?

Do insiders & institutionals have more ownership in ALNY or PTGX?

Do analysts recommend ALNY or PTGX?

Which has preferable valuation & earnings, ALNY or PTGX?

Is ALNY or PTGX more profitable?

Summary

How does Protagonist Therapeutics compare to Insmed?

Does the media prefer PTGX or INSM?

Which has more risk and volatility, PTGX or INSM?

Which has better earnings and valuation, PTGX or INSM?

Do insiders and institutionals hold more shares of PTGX or INSM?

Is PTGX or INSM more profitable?

Do analysts prefer PTGX or INSM?

Summary

How does Protagonist Therapeutics compare to Roivant Sciences?

Does the media refer more to PTGX or ROIV?

Do insiders and institutionals have more ownership in PTGX or ROIV?

Which has more volatility and risk, PTGX or ROIV?

Do analysts recommend PTGX or ROIV?

Which has stronger valuation & earnings, PTGX or ROIV?

Is PTGX or ROIV more profitable?

Summary

How does Protagonist Therapeutics compare to Incyte?

Do institutionals and insiders hold more shares of PTGX or INCY?

Does the media refer more to PTGX or INCY?

Is PTGX or INCY more profitable?

Which has stronger valuation and earnings, PTGX or INCY?

Which has more volatility and risk, PTGX or INCY?

Do analysts recommend PTGX or INCY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTGX vs. The Competition

Protagonist Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools